'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout
Survival Gains In Third Line Patients
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.
